Proteomics International Laboratories Ltd (ASX: PIQ) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Proteomics International Laboratories Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $117.15 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 130.89 million
Earnings per share -0.049
Dividend per share N/A
Year To Date Return 3.91%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Proteomics International Laboratories Ltd (ASX: PIQ)
    Latest News

    one hundred dollar notes planted in the ground representing growth asx shares
    Small Cap Shares

    'Richest pipeline' in ASX: Expert names 3 small-cap shares to buy

    Ask A Fund Manager: Alto Capital's Tony Locantro also reveals what his biggest regret in investing is.

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Ask a Fund Manager

    2 'outstanding' small-cap ASX shares that could explode: expert

    Ask A Fund Manager: Alto Capital's Tony Locantro reveals a pair of small caps that he reckons have a bright…

    Read more »

    Jumping asx share price represented by young girl smiling and jumping up
    Share Market News

    Proteomics International (ASX:PIQ) share price jumps after diabetes study readouts

    The biotechnology research company's share price is in the green today.

    Read more »

    pause in medical asx share price represented by doctor holding hand up in stop motion
    Share Market News

    Here's why the Proteomics International (ASX:PIQ) share price is halted

    The shares in the medical technology company were last trading at 99.5 cents.

    Read more »

    A man stands with arms crossed in front of a giant shadow of a body builder representing ASX small-cap stocks.
    Ask a Fund Manager

    2 small-cap ASX shares with huge potential: fund manager

    Ask a fund manager Part 2: Kardinia Capital's Kristiaan Rehder reveals his pick of 2 promising small-cap ASX shares.

    Read more »

    asx share price fall represented by lady in striped tshirt making sad face against orange background
    Healthcare Shares

    Why the Proteomics (ASX:PIQ) share price is flying 5%

    The Proteomics (ASX: PIQ) share price was off to a good start today before falling flat on news it has…

    Read more »

    PIQ ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Proteomics International Laboratories Ltd

    Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company was founded by Richard Lipscombe and Bill Parker in 2001 and is headquartered in Perth, Australia.

    PIQ Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jun 2024 $0.90 $-0.04 -4.30% 167,302 $0.93 $0.94 $0.90
    12 Jun 2024 $0.93 $-0.01 -1.06% 55,381 $0.93 $0.93 $0.91
    11 Jun 2024 $0.94 $-0.01 -1.05% 184,531 $0.96 $0.96 $0.91
    07 Jun 2024 $0.95 $0.00 0.00% 56,053 $0.95 $0.95 $0.94
    06 Jun 2024 $0.95 $-0.01 -1.04% 151,606 $0.97 $0.98 $0.95
    05 Jun 2024 $0.96 $-0.03 -3.03% 138,375 $0.97 $0.99 $0.96
    04 Jun 2024 $0.99 $0.01 1.02% 73,794 $1.00 $1.01 $0.98
    03 Jun 2024 $0.99 $0.02 2.06% 69,987 $0.98 $0.99 $0.97
    31 May 2024 $0.97 $-0.02 -2.02% 83,263 $0.99 $0.99 $0.97
    30 May 2024 $0.99 $0.00 0.00% 221,817 $1.01 $1.01 $0.99
    29 May 2024 $0.99 $0.01 1.02% 174,449 $1.00 $1.00 $0.99
    28 May 2024 $0.98 $-0.05 -4.83% 130,591 $1.04 $1.04 $0.98
    27 May 2024 $1.04 $0.01 0.98% 44,546 $1.03 $1.04 $1.01
    24 May 2024 $1.02 $0.03 3.03% 43,286 $0.99 $1.02 $0.99
    23 May 2024 $0.99 $0.01 1.02% 167,387 $0.99 $0.99 $0.98
    22 May 2024 $0.99 $-0.01 -1.01% 120,253 $1.01 $1.02 $0.98
    21 May 2024 $0.99 $-0.04 -3.88% 353,902 $1.03 $1.03 $0.99
    20 May 2024 $1.03 $0.00 0.00% 79,756 $1.03 $1.03 $1.03
    17 May 2024 $1.03 $-0.01 -0.96% 201,098 $1.06 $1.06 $1.03
    16 May 2024 $1.05 $-0.01 -0.95% 79,657 $1.07 $1.07 $1.05
    15 May 2024 $1.05 $-0.01 -0.94% 97,795 $1.07 $1.07 $1.04

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 Jan 2024 Richard Lipscombe Sell 2,631,579 $2,000,000

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Paul Edward House Non-Executive Director Nov 2017
    Mr House has over 30 years experience with multi-national corporations and is currently CEO of Imdex. He previously served eight years as the Managing Director of SGS India, where he was responsible for a workforce of 4,500 personnel and 38 laboratories; SGS is the world's leading Testing, Inspection and Certification (TIC) company. Mr House has previously held CFO and COO roles and has a record for delivery of business performance targets, revenue growth, margin improvement, market share and productivity, across multiple services, markets and borders.
    Dr Robyn Elliott Non-Executive Director Nov 2021
    Dr Elliot is Global Head, Strategic Portfolio Management within the Global Network Strategy team of CSL Behring, a subsidiary of CSL Limited. Her role is responsible for governance and business value delivery oversight for a multi billion dollar global capital expansion portfolio. She is also a non-executive director of PolyNovo Limited. Robyn's 9 years at CSL Behring have included Senior Director roles for Strategic Program Management, Strategic Expansion Projects and Quality, including supporting the global network strategy team determining the ten-year expansion plan for the CSL Behring global business. Prior to CSL Behring she was Managing Director at IDT Australia Ltd and commenced her career at DBL Faulding. Robyn has a track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy
    Dr Richard Lipscombe Managing Director Jun 2014
    Dr Lipscombe is a business manager and protein chemist expert in analysing biomolecules using proteomics techniques. He has expertise in chemistry, immunology, mass spectrometry, peptide synthesis, high performance computing and robotics. Richard has international experience in both science and business gained over a 30 year period in Australia, USA and the UK, including work in hospital and academic laboratories and commercial organisations. After managing the Protein Analysis Facility at the University of Western Australia, he co-founded Proteomics International Pty Ltd in 2001. Richard is well published in peer review journals, and holder of several patents.
    Mr Ian Roger Moore Non-Executive Director Oct 2016
    Mr Moore has 40 years experience in the international pharmaceutical industry, including almost 30 years as President of Novo Nordisk Japan (Novo Nordisk is the world's largest manufacturer of diabetes therapeutics including Insulin and a global leader in diabetes care). Roger established Novo's organisation in Japan as the first employee in 1977, and worked for the company until his retirement as Chairman at the end of 2007. In 2000 Roger was appointed Senior Vice President, responsible for Novo Nordisk's business in Japan, Australia, New Zealand and the Pacific , and also a member of the Senior Management Board of Novo Nordisk A/S. In 2007, Roger was awarded the Knight's Cross of the Order of the Dannebrog(R) by Queen Margrethe II of Denmark.
    Mr Neville Gardiner Non-Executive ChairmanNon-Executive Director Nov 2021
    Mr Gardiner was recently a Partner of Deloitte in its Mergers & Acquisitions Advisory team. He is a seasoned finance professional with over 30 years experience advising Boards of public and private companies on mergers and acquisitions, project development, equity and debt capital markets, transaction structuring, capital allocation and complex commercial problem solving. Prior to Deloitte Neville was Co-Founder and Managing Director of Torridon Partners, an independent corporate advisory firm. Torridon Partners was acquired by Deloitte in 2016. He has held leadership positions at Macquarie Bank, Bank of America Merrill Lynch and Arthur Andersen, and has broad industry sector exposure including healthtech, fin-tech, mining and mining services, infrastructure, energy, and fabrication and construction.
    Ms Karen Logan Company Secretary
    Karen Logan Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Richard Lipscombe 19,048,704 15.57%
    Mr John Sutherland Richardson Dunlop 3,855,188 3.15%
    Mr Dirk Charles Hawker Van Dissel <D & T Van Dissel Family A/C> 2,285,842 1.87%
    National Nominees Limited 2,235,651 1.83%
    Himstedt & Co Pty Ltd <The Himstedt Family A/C> 2,136,471 1.75%
    Randolph Resources Pty Limited 1,949,000 1.59%
    Sparrow Holdings Pty Ltd <Sweet Super Fund A/C> 1,920,500 1.57%
    Altor Capital Management Pty Ltd <Altor Alpha Fund A/C> 1,660,000 1.36%
    Xylo Pty Ltd <The Parker Family A/C> 1,503,700 1.23%
    Mccusker Holdings Pty Ltd 1,500,000 1.23%
    Mrs Lisa Floan 1,363,235 1.11%
    J P Morgan Nominees Australia Pty Limited 1,308,571 1.07%
    BNP Paribas Noms Pty Ltd <DRP> 1,218,368 1.00%
    Mr Konrad Floan 1,120,000 0.92%
    Moore & Sotomi Investments Pty Ltd <Roger Moore Family A/C> 975,824 0.80%
    Jetan Pty Ltd 950,000 0.78%
    Bfm Superannuation Fund Pty Ltd 944,500 0.77%
    Bond Street Custodians Limited <Lam1 - D08047 A/C> 911,765 0.75%
    Candour Advisory Pty Ltd 843,750 0.69%
    Quintal Pty Ltd <Harken Family A/C> 790,000 0.65%